PatientsVille.com Logo

Neoplasm malignant and Zytiga

PatientsVille

Neoplasm Malignant Symptoms and Causes

Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body.

Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for where they start. For example, lung cancer starts in the lung, and breast cancer starts in the breast. The spread of cancer from one part of the body to another is called metastasis. Symptoms and treatment depend on the cancer type and how advanced it is. Most treatment plans may include surgery, radiation and/or chemotherapy. Some may involve hormone therapy, immunotherapy or other types of biologic therapy, or stem cell transplantation.

NIH: National Cancer Institute

Check out the latest treatments for neoplasm malignant

neoplasm malignant treatment research studies

Zytiga clinical trials, surveys and public health registries


Find Drug Side Effect reports



Zytiga Side Effects

Prostatic Specific Antigen Increased (72)
Death (71)
Nausea (36)
Asthenia (34)
Fatigue (34)
Dyspnoea (29)
Oedema Peripheral (27)
Vomiting (26)
Cardiac Failure (26)
Disease Progression (25)
Decreased Appetite (23)
Myocardial Infarction (22)
Hypokalaemia (21)
Prostate Cancer (21)
Pain In Extremity (21)
Pain (20)
Dehydration (20)
Malaise (20)
Weight Decreased (19)
Urinary Tract Infection (18)
Local Swelling (18)
Dizziness (18)
Anaemia (18)
Atrial Fibrillation (17)
Pneumonia (17)
Headache (16)
Pleural Effusion (15)
Hypotension (15)
Dysphagia (14)
Cardiac Disorder (14)
Diarrhoea (14)
Chest Pain (13)
Myalgia (13)
Thrombocytopenia (13)
Renal Failure (13)
Bone Pain (12)
Blood Potassium Decreased (12)
Fall (12)
Blood Alkaline Phosphatase Increased (12)
Blood Glucose Increased (12)
Pyrexia (12)
Fluid Retention (12)
Oedema (12)
Renal Failure Acute (12)
Hypertension (12)
Haematuria (12)
Cystitis (11)
Gait Disturbance (11)
Muscular Weakness (11)
Incorrect Dose Administered (11)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Neoplasm Malignant Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)
Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate + prednisone + LHRH-therapy;   Drug: abiraterone acetate + prednisone
Outcome Measures: radiographic-progression-free survival;   Correlation of radiographic-progression-free survival with early PSA-response;   Hormonal analyses;   Adverse Events
2 Recruiting 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
Condition: Prostate Cancer
Interventions: Drug: Abiraterone acetate;   Drug: Abiraterone acetate plus degarelix;   Drug: Degarelix
Outcome Measures: progression-free survival (PFS);   Soft tissue complete response;   PSA response rate;   overall quality of life;   non-hematologic adverse events;   Testosterone and luteinizing hormone (LH) recovery rates;   Correlative tissue analysis
3 Recruiting Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
Condition: Prostate Cancer
Interventions: Drug: Abiraterone Acetate;   Drug: Prednisone;   Drug: Enzalutamide;   Drug: LHRHa
Outcome Measure: Difference in Pathologic Stage < pT2 at Prostatectomy
4 Not yet recruiting A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Conditions: Prostatic Neoplasms;   Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions: Drug: Abiraterone Acetate;   Drug: Prednisone;   Drug: JNJ-56021927
Outcome Measures: Area Under the Plasmas Concentration Curve (AUC) 0- 24h of abiraterone;   Maximum plasma concentration (Cmax) of abiraterone;   Change in prostate specific antigen (PSA);   Maximal decline in prostate specific antigen (PSA);   Area Under the Plasma Concentration Curve (AUC) 0- 24h of JNJ-56021927 when given with abiraterone acetate (AA);   Maximum plasma concentration (Cmax) of JNJ-56021927 when given with abiraterone acetate (AA)
5 Recruiting A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
Condition: Prostate Neoplasms
Interventions: Drug: Abiraterone acetate;   Drug: Prednisone;   Other: Androgen deprivation therapy (ADT);   Drug: Abiraterone acetate Placebo;   Drug: Prednisone Placebo
Outcome Measures: Overall Survival (OS);   Radiographic progression-free survival (PFS);   Time to next skeletal-related event;   Time to prostate specific antigen (PSA) progression;   Time to next subsequent therapy for prostate cancer;   Time to initiation of chemotherapy;   Time to Pain Progression
6 Recruiting Abiraterone Acetate for Castrate Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Abiraterone;   Drug: Prednisone
Outcome Measures: Assessment of AR signaling in CTCs and correlation with response;   Change in number and proliferative fraction of CTCs with abiraterone treatment
7 Not yet recruiting RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistant (The RESTORE Study)
Condition: Prostate Cancer
Interventions: Drug: Testosterone cypionate;   Drug: Testosterone Enanthate;   Drug: Abiraterone acetate;   Drug: Enzalutamide
Outcome Measures: PSA response to Bipolar Androgen Therapy;   PSA response to enzalutamide or abiraterone acetate post Bipolar Androgen Therapy;   PSA progression on enzalutamide or abiraterone acetate post-BAT;   PSA progression on BAT (Bipolar Androgen Therapy );   Measurable disease response;   initiation of docetaxel chemotherapy;   Quality of life;   Safety and Tolerability;   Fasting glucose;   hemoglobin A1c;   Fasting insulin;   Serum N-telopeptide;   Osteocalcin
8 Recruiting Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone
Condition: Prostate Cancer
Interventions: Drug: Lupron;   Drug: Zoladex;   Drug: Degarelix;   Drug: Abiraterone Acetate;   Drug: Prednisone
Outcome Measure: Prostate Specific Antigen (PSA) Free Survival
9 Recruiting Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: abiraterone acetate;   Drug: prednisone;   Drug: veliparib;   Other: laboratory biomarker analysis
Outcome Measures: Confirmed PSA response rate;   Rates of PSA decline;   Objective response rates;   Progression-free survival;   Grade 4 or greater toxicity of abiraterone acetate and abiraterone acetate + veliparib graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
10 Recruiting Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: abiraterone acetate;   Drug: dasatinib;   Drug: prednisone
Outcome Measures: Progression-free survival (PFS);   Overall response;   PSA change response according to PSA Working Group Criteria 2;   Overall survival;   Intent-to-treat analysis
11 Recruiting Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: Alisertib;   Drug: Abiraterone acetate;   Drug: Prednisone
Outcome Measures: Phase I: Frequency of dose limiting toxicities of Alisertib, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.1;   Phase II: Duration of progression free survival according to the PCWG2 criteria;   Change in PSA kinetics
12 Recruiting Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer
Condition: Metastatic Castration-resistant Prostate Cancer
Interventions: Drug: Olaparib;   Drug: Placebo;   Drug: Abiraterone;   Drug: Prednisone or prednisolone
Outcome Measures: Part A. • To evaluate the safety, tolerability of daily olaparib when given in addition to abiraterone and prednisolone.;   Part B. Radiologic Progression-Free Survival (rPFS).;   Part A: Olaparib and abiraterone PK parameters: AUCss. Cmax ss, tmax ss, Cmin ss.;   Part B: Overall survival (OS).;   Part B: The time to second progression (PFS2);   Part B: Response to treatment as shown by Overall Response Rates (ORR), changes in PSA levels, change in CTC levels over time and measurement of time to requiring further prostate cancer treatment;   Part B: To evaluate the safety, tolerability of daily olaparib when given in addition to abiraterone and prednisolone;   Part B: ERG expression/fusion status
13 Recruiting Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Abiraterone;   Drug: ABT-263;   Drug: Hydroxychloroquine
Outcome Measures: Biochemical response to ABT-263 and Abiraterone and to ABT-263 in combination with Hydroxychloroquine and Abiraterone in patients that are progressing on Abiraterone;   Time to PSA progression;   Progression Free Survival;   Measurable tumor response in patients with measurable disease;   Circulating tumor cells pre-enrollment and during therapy;   Bcl-2 family protein expression (Bcl-2, Bcl-XL, MCL-1) in paraffin blocks when available by immunohistochemistry;   Biomarkers of autophagy modulation by EM; and LC3, and/or p62 by immunoblotting in PBMC and tumor tissue when available;   Overall survival
14 Recruiting Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.
Condition: Metastatic Prostate Cancer
Interventions: Drug: Docetaxel, prednisone, abiraterone;   Drug: Docetaxel, prednisone
Outcome Measures: 1 year radiologic progression free survival;   Overall survival;   Radiologic progression free survival;   PSA progression free survival;   PSA response rate;   Objective response rate;   Quality of life;   Time to skeletal-related event;   Time to opiate use for cancer pain;   Time to pain progression;   Safety profile
15 Recruiting Abiraterone Acetate Trial in African American Prostate Cancer Patients
Condition: Prostate Cancer
Intervention: Drug: Abiraterone Acetate
Outcome Measures: The percent change in PSA;   Time to progression;   RECIST;   bone scan;   safety of abiraterone;   Testosterone
16 Recruiting A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer
Condition: Castration Resistant Prostate Cancer
Interventions: Drug: Abiraterone Acetate;   Drug: Prednisone
Outcome Measures: PSA response proportion to increased-dose Abiraterone Acetate for patients who experienced disease progression following standard dose Abiraterone Acetate therapy;   Safety of treatment;   Clinical benefit (time to PSA progression and progression free survival) for patients treated with increased dose Abiraterone Acetate;   Serum concentration of Abiraterone Acetate;   Circulating androgen levels
17 Recruiting Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
Conditions: Castration-resistant Prostate Cancer;   Stage IV Prostate Cancer
Intervention: Drug: abiraterone acetate
Outcome Measures: Change in PSA level;   Progression-free survival (PFS);   Peak Plasma Concentration (Cmax) of abiraterone acetate, obtained from steady states PK samples;   The effects of dosing arm percentage change on adrenal androgen production (DHEA, DHEA-S);   Incidence of adverse events (AEs)
18 Recruiting Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: abiraterone acetate;   Drug: prednisone;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Change in tissue testosterone, dihydrotestosterone (DHT), androstenedione and dehydroepiandrosterone (DHEA);   Ability of abiraterone acetate to suppress tumor testosterone, assessed by changes in testosterone levels;   Tissue testosterone from metastasis at time of progression;   PSA response to dose escalation of abiraterone acetate, defined as decline from the PSA at initiation of therapy and with dose escalation of abiraterone acetate, assessed using Prostate Cancer Working Group 2 (PCWG2) criteria;   Potential mechanisms of resistance to abiraterone acetate, determined by assessment of changes in tissue androgen levels, evaluating wild type and splice variant AR levels, and cDNA microarray;   Reflection of molecular changes in tumor metastases by microRNA (miRNA) acquired from peripheral blood
19 Recruiting Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: Abiraterone;   Drug: Prednisolone
Outcome Measures: Impact of baseline uPAR cleavage products on response.;   Impact of baseline plasma concentration of uPAR cleavage products on overall survival (OS).;   Impact of baseline plasma concentration of uPAR cleavage products on progression free survival (PFS).;   Impact of baseline plasma concentration of uPAR cleavage products on pain relief rate.;   Impact of baseline plasma concentration of uPAR cleavage products on disease control rate (DCR).;   Impact of baseline plasma concentration of uPAR cleavage products on serious adverse events (SAE).
20 Recruiting Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Condition: Prostate Cancer
Interventions: Drug: Dovitinib;   Drug: Abiraterone Acetate;   Drug: Prednisone
Outcome Measure: Change in Gene Expression